bluebird bio, a clinical-stage biotech developing gene therapies for severe genetic and orphan diseases, raised $101 million by offering 5.9 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 5.0 million shares. bluebird bio will list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on 3/21/2013. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.
